IP Library Granted Patent US 8,658,360
Granted Patent B2
US 8,658,360 · App. 13/223,904 · Granted Feb 25, 2014

Nucleic acid purification with a binding matrix

Inventors: Rex M. Bitner (Cedarburg, WI); Michelle M. Mandreker (Oregon, WI); Paula R. Brisco (Oregon, WI)
Assignee: Promega Corporation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,658,360
App. No.
13/223,904
Granted
Feb 25, 2014
Kind
B2
Abstract

The present invention relates to methods, kits, and compositions for generating purified RNA samples and purified DNA samples. In particular, the present invention provides methods for generating a purified RNA or DNA sample from a sample containing both DNA and RNA molecules using a binding matrix that preferentially binds DNA or RNA in the presence of an acidic dilution buffer, or using a binding matrix that comprises acid zeolites, as well as compositions and kits for practicing such methods.

Claims (19)

1. A method of generating a purified RNA and purified DNA sample from an initial sample that comprises DNA and RNA molecules, said method comprising;

a) contacting said initial sample with; i) a dilution buffer with an acidic pH, and ii) a nucleic acid binding matrix, which comprises a zeolite, that preferentially binds both single and double stranded DNA molecules in the presence of said dilution buffer, wherein said contacting generates a DNA-bound binding matrix which is substantially RNA free; and

b) physically separating said DNA-bound binding matrix from said initial sample the remaining initial sample now being a purified RNA sample comprising a plurality of RNA molecules;

c) contacting the DNA-bound binding matrix with an elution buffer; and

d) eluting DNA bound to the DNA-bound binding matrix thereby generating a purified DNA sample comprising a plurality of DNA molecules.

2. The method of claim 1 , wherein said binding matrix is configured to not bind double stranded or single stranded RNA molecules.

3. The method of claim 1 , wherein said initial sample comprises a cell lysate, wherein said cell lysate comprises lysed cells, and wherein said plurality of eluted RNA molecules are present in said purified RNA preparation at a level of at least 5 μg of RNA per 1 million of said lysed cells present in said sample.

4. The method of claim 1 , wherein said purified RNA sample is substantially DNA-free.

5. The method of claim 1 , wherein said purified DNA is substantially RNA-free.

6. The method of claim 1 , wherein said separating comprises centrifuging said initial sample such that a pellet forms which contains said DNA-bound binding matrix, and separating said pellet from the remainder of said initial sample.

7. The method of claim 1 , wherein said binding matrix further comprises Fe 3 O 4 and said separating comprises magnetic separation of said DNA-bound binding matrix from said initial sample.

8. The method of claim 1 , wherein said eluting comprises centrifuging said DNA-bound binding matrix such that a pellet forms which contains said binding matrix, and separating said pellet from the remainder of the sample.

9. The method of claim 1 , wherein said sample comprises a cell lysate.

10. The method of claim 9 , wherein said cell lysate comprises nonnucleic acid cellular debris, and wherein separating said RNA-bound binding matrix serves to remove a substantial proportion of said non-nucleic acid cellular debris from said initial sample.

11. The method of claim 1 , wherein said binding matrix comprises a membrane coated with binding particles.

12. The method of claim 11 , wherein said binding matrix comprises silicon.

13. The method of claim 1 , wherein said binding matrix comprises pores, wherein said pores are about 3 Å to 100 Å in size.

14. The method of claim 1 , wherein said dilution buffer has a pH of about 5.3 or less.

15. The method of claim 1 , wherein said DNA molecules in said sample comprise genomic DNA molecules.

Assignments (2)
SECURITY INTEREST Recorded Apr 3, 2019
From: PROMEGA CORPORATION; PROMEGA BIOSCIENCES, LLC; TERSO SOLUTIONS, INC.; ORION SEVEN, LLC; PROMEGA AVIATION LLC
To: JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT
Reel/Frame 048790/0259 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 29, 2014
From: BITNER, REX M.; BRISCO, PAULA R.; MANDREKER, MICHELLE M.
To: PROMEGA CORPORATION
Reel/Frame 033206/0291 →
Continuity (3)
Continuation 11636174 · Dec 8, 2006
Provisional Application 60748825 · Dec 9, 2005
Related Publication 20120059160A1 · Mar 8, 2012